A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2012
At a glance
- Drugs FFP 102 (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 03 Jun 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
- 03 Jun 2010 Planned end date changed from 1 Nov 2009 to 1 May 2010 as reported by ClinicalTrials.gov.